Safety And Efficacy Of Glucagon-Like Peptide-1 Receptor Agonists And Their Effect On Weight Loss

Abstract

Obesity can substantially harm human health, increasing the risk of diabetes mellitus (DM) and other negative effects. To lose weight, successful therapy methods and drugs have been developed. Glucagon-like peptide-1 receptor agonists (GLP-1Ras) are indicated for weight loss in obese persons with or without type 2 diabetes (T2DM). The aim of this research to provide an overview of the safety and efficacy of gluc[1]agon-like peptide-1 receptor agonists and to determine whether treatment with a glucagon-like peptide-1 receptor leads to weight loss in overweight or obese patients with or without type 2 diabetes.  The current research offers evidence that GLP-1R agonist medication results in weight loss in overweight or obese people with or without type 2 diabetes mellitus. Given its potential benefits in lowering weight in addition to glycemic management, GLP-1 agonists may soon be used to treat obesity in both diabetic and non-diabetic persons. However, further research investigations, namely big clinical trials, are necessary to extend and fully explain the beneficial effects and potential negative effects of GLP-1 agonists. Obesity therapies based on glucagon-like peptide-1 (GLP-1) agonism are now being used and further developed. GLP-1 RA as an addition to LSI is effective and safe in adolescents with obesity who do not react well to lifestyle interventions. Since of the scarcity of data, a general advice is to favor long acting GLP-1 RA over short acting GLP-1 RA since they are licensed for the treatment of obesity and have greater tolerability, safety, and therapeutic response impact.